We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
The current IFTBF market cap is 106.75M. The company's latest EPS is SEK -9.4536 and P/E is -0.87.
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| SEK (SEK) | SEK (SEK) | SEK (SEK) | SEK (SEK) | SEK (SEK) | |
| Total Revenue | 0 | 0 | 0 | 0 | 0 |
| Operating Income | -47.2M | -71.92M | -44.58M | -65.81M | -134.62M |
| Net Income | -46.32M | -72.01M | -44.99M | -65.45M | -123.07M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| SEK (SEK) | SEK (SEK) | SEK (SEK) | SEK (SEK) | SEK (SEK) | |
| Total Assets | 518.27M | 450.32M | 408.48M | 349.62M | 351.34M |
| Total Liabilities | 7.88M | 10.16M | 13.22M | 17.91M | 46.18M |
| Total Equity | 510.4M | 440.15M | 395.25M | 331.71M | 305.15M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| SEK (SEK) | SEK (SEK) | SEK (SEK) | SEK (SEK) | SEK (SEK) | |
| Operating | -51.3M | -58.39M | -55.62M | -85.8M | -101.22M |
| Investing | N/A | N/A | N/A | N/A | N/A |
| Financing | N/A | 1.76M | 91k | 1.88M | 96.52M |
| Market Cap | 106.75M |
| Price to Earnings Ratio | -0.87 |
| Price to Sales Ratio | 0 |
| Price to Cash Ratio | 0.32 |
| Price to Book Ratio | 0.35 |
| Dividend Yield | - |
| Shares Outstanding | 13.02M |
| Average Volume (1 week) | 0 |
| Average Volume (1 Month) | 863 |
| 52 Week Change | 9.77% |
| 52 Week High | 8.38 |
| 52 Week Low | 7.47 |
| Spread (Intraday) | 0 (0%) |
| Company Name | Infant Bacterial Therapeutics AB (GM) |
| Address |
bryggargatan 10 stockholm SE-111 21 |
| Website | https://www.ibtherapeutics.com |
| Industry | pharmaceutical preparations (2834) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
